Apollo, Lusha, ZoomInfo: the hospital data they miss in 2026

ZoomInfo claims 321 million professional profiles, and Apollo more than 230 million verified contacts (Apollo.io, 2026). Neither one knows that a CHU (university hospital) published a tender for two MRI scanners this morning.

Apollo, Lusha, and ZoomInfo are static contact databases: they give you a name, an email, sometimes a cell phone number. When you sell to a French hospital, two limitations stack up. Their data accuracy drops in Europe: an independent test on 1,000 contacts measured a 78% email match rate for Apollo and 84% for ZoomInfo (Cleanlist, 2026). And none of these databases contains the public buying signals that put a date on a hospital decision.

This article breaks down what these three tools actually deliver, why their data degrades in the French healthcare market, which hospital data they miss by design, and how to connect a contact database to public buying signals.

What do Apollo, Lusha, and ZoomInfo really give you?

These three tools sell volume: static contact data made up of professional identities, emails, and phone numbers, aggregated at very large scale. Apollo advertises more than 230 million verified contacts and 30 million companies. ZoomInfo claims 321 million profiles, 174 million emails, and 70 million direct dials. Lusha relies on enrichment from LinkedIn profiles. These are identity directories, not timing engines.

On their own turf, these tools work well: finding contact details, enriching a CRM, building a list of names by title and industry. The data is abundant and global. The limitation isn’t volume; it’s the nature of the data: a contact is a static record, not a dated event. Apollo’s contact enrichment describes an engine that syncs titles, employer changes, and funding rounds, but it remains an identity layer built on self-reported and purchased data.

Why does their data degrade in the French healthcare market?

Because these databases are North American first, and their European coverage is weaker. Users report that ZoomInfo data is strong in the United States but that direct emails and cell numbers are thin in EMEA (Cognism, 2026). Access to European data is billed separately through a Data Passport. Lusha depends on LinkedIn profiles: strong on active professionals, blind to everyone else. In a market where the decision-maker isn’t always online, real coverage collapses.

Then there’s the regulatory constraint. Targeting French healthcare professionals means complying with the GDPR and national do-not-contact lists: ZoomInfo covers only some of the European opt-out lists for direct marketing. Buying a database of healthcare contact details means buying an asset that expires and whose compliance is never guaranteed, a point developed in why a healthcare B2B database is an asset that’s already dead. A high volume of names doesn’t make up for outdated data and partial coverage.

Which French hospital data do these tools not contain?

They contain none of the public buying signals of the French healthcare system. The BOAMP (France’s official public procurement bulletin), ARS (regional health agencies), HAS (France’s National Authority for Health), RPPS (France’s national registry of healthcare professionals), and EUDAMED are official registries that can legally be consulted and that put a date on a decision: a tender commits a budget, an ARS authorization unlocks heavy equipment, an HAS inspection requires compliance upgrades. Apollo, Lusha, and ZoomInfo deliver a buyer’s identity; these registries deliver the moment they buy. The two don’t overlap at all.

The scale is massive. The BOAMP publishes about 200,000 public procurement notices every year (data.gouv.fr, BOAMP), including hospital equipment purchases above regulatory thresholds. The RPPS lists more than 1.8 million identified and verifiable healthcare professionals, regardless of any online presence (Annuaire Santé, esante.gouv.fr). These eight registries, and what each one signals, are covered source by source in our analysis of the hospital buying signals a prospecting tool ignores. None of these streams feeds a general-purpose contact database.

Is a static name enough to sell to a French hospital?

No. A static name starts a list, not a sales cycle. Apollo gives you a name; selling to a hospital takes the name, plus the context, plus the right moment, plus the message that connects the signal to your offer. Contacting a CIO because they’re in a database means showing up without knowing whether their facility is preparing a purchase. Contacting them because their facility just published a tender and a new head of department has taken office means showing up inside the window.

That’s the difference between identity data and intent data. Contact databases answer “who exists”; the French hospital market rewards “who’s buying, and when.” With long cycles and large deal sizes, a message sent to the right person in the wrong window is a wasted message. Volume then amplifies the noise; it doesn’t create the opportunity.

How do you combine a contact database with public buying signals?

Keep the identity tool to reach the right person, and add monitoring of public sources to date the purchase. A public signal identifies the facility ready to buy; a database like Apollo or ZoomInfo then provides the contact details. That’s Agify’s role: it continuously monitors public healthcare registries (BOAMP, ARS, HAS, RPPS, EUDAMED), qualifies each facility, and pushes the dated file to the top of the list. The contact database becomes useful again once it’s connected to timing.

The agent sorts leads by the signal detected (qualified with an active signal, qualified on watch, or out of scope) to focus effort where a window is open. That’s exactly what we scope in a MedTech prospecting scoping call: translating a product catalog into public signals to monitor, then connecting that detection to the tools your reps already use. For a French MedTech company specializing in medical imaging, cross-referencing more than ten public sources made it possible, in six weeks, to keep only the European radiologists who were truly qualified, as detailed in this case study on prospecting radiologists through buying signals. The overall approach is the backbone of the guide to MedTech prospecting through buying signals.

Frequently asked questions

Do Apollo or ZoomInfo cover hospital tenders?

No. Apollo and ZoomInfo are contact databases: identities, emails, phone numbers. Hospital tenders are published in the BOAMP, an official registry none of these databases reads. To capture these buying signals, you need dedicated monitoring of public sources, connected to the contact database to reach the right person.

Is the data from Apollo and ZoomInfo reliable in France?

Partly. These databases are North American first, and their European coverage is weaker. An independent test on 1,000 contacts measured a 78% email match rate for Apollo and 84% for ZoomInfo, and users report thin direct email and cell coverage in EMEA. Access to ZoomInfo’s European data is billed separately.

Is Lusha better than Apollo for healthcare in France?

Not structurally. Lusha relies on LinkedIn profiles: its coverage is strong for professionals who are active on the network, but nonexistent for those who aren’t there. In the French hospital market, where many decision-makers don’t keep an up-to-date profile, this LinkedIn dependence leaves gaps that volume doesn’t fill.

Should you replace Apollo or ZoomInfo with public-source monitoring?

No. The two layers complement each other: the contact database for identity and contact details, public monitoring for timing. A database alone prospects blind to the buying window; monitoring alone detects the moment without the contact details. Combining the two is what turns a name into a dated opportunity.

Is it legal to use these public healthcare signals?

Yes. The BOAMP, ARS, HAS, RPPS, and EUDAMED are public, official registries that can legally be consulted. Using them doesn’t touch any patient data or internal hospital system. It’s traceable public data, GDPR compliant, with a verifiable source for every signal detected.

Conclusion

Apollo, Lusha, and ZoomInfo are solid identity databases, but they’re directories of static names, weaker in Europe and silent on timing. Three takeaways: their accuracy degrades in the French market and their healthcare coverage there is partial; the public buying signals of the French hospital system (BOAMP, ARS, HAS, RPPS, EUDAMED) aren’t in any of these databases; and a name without context or timing doesn’t open a sales cycle on long, high-value deals.

The remaining question is which signals matter in your specific market. Let’s take 30 minutes to look at the public sources that announce your opportunities and how to connect them to the contact database your reps already use.

---

Agify deploys autonomous AI prospecting agents in B2B sales teams, specializing in the French MedTech market and its public healthcare and procurement sources.